Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitals | 2 | 2019 | 143 | 1.090 |
Why?
|
| Intensive Care Units | 8 | 2019 | 266 | 1.070 |
Why?
|
| Acute Lung Injury | 6 | 2018 | 18 | 0.800 |
Why?
|
| Critical Illness | 5 | 2021 | 126 | 0.720 |
Why?
|
| Quality of Health Care | 2 | 2019 | 117 | 0.670 |
Why?
|
| Energy Intake | 6 | 2020 | 72 | 0.660 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 35 | 0.660 |
Why?
|
| Enteral Nutrition | 5 | 2021 | 58 | 0.570 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2019 | 37 | 0.560 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 119 | 0.540 |
Why?
|
| Heart Valves | 1 | 2016 | 2 | 0.530 |
Why?
|
| Endocarditis | 1 | 2016 | 6 | 0.530 |
Why?
|
| Public Health | 2 | 2022 | 66 | 0.530 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 34 | 0.520 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 27 | 0.510 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 17 | 0.500 |
Why?
|
| Civil Defense | 1 | 2015 | 5 | 0.500 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 7 | 0.500 |
Why?
|
| Patient Safety | 1 | 2016 | 49 | 0.500 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2020 | 18 | 0.490 |
Why?
|
| Physicians | 2 | 2014 | 112 | 0.470 |
Why?
|
| Terminal Care | 1 | 2014 | 21 | 0.460 |
Why?
|
| Attitude of Health Personnel | 2 | 2014 | 146 | 0.430 |
Why?
|
| Stroke | 1 | 2016 | 259 | 0.420 |
Why?
|
| Clinical Competence | 2 | 2014 | 217 | 0.410 |
Why?
|
| Nutritional Support | 4 | 2021 | 19 | 0.400 |
Why?
|
| Internship and Residency | 2 | 2014 | 196 | 0.380 |
Why?
|
| C-Reactive Protein | 3 | 2016 | 105 | 0.350 |
Why?
|
| Parenteral Nutrition | 4 | 2021 | 21 | 0.340 |
Why?
|
| Urinary Catheterization | 1 | 2009 | 7 | 0.340 |
Why?
|
| Humans | 26 | 2022 | 25692 | 0.330 |
Why?
|
| Catheter-Related Infections | 1 | 2009 | 15 | 0.330 |
Why?
|
| Chicago | 4 | 2016 | 869 | 0.330 |
Why?
|
| Urinary Tract Infections | 1 | 2009 | 30 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 284 | 0.310 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2005 | 3 | 0.250 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 16 | 0.250 |
Why?
|
| Methotrexate | 1 | 2005 | 34 | 0.240 |
Why?
|
| Male | 16 | 2020 | 13917 | 0.240 |
Why?
|
| Female | 15 | 2020 | 14273 | 0.230 |
Why?
|
| Lung | 1 | 2005 | 159 | 0.230 |
Why?
|
| Adult | 9 | 2019 | 7336 | 0.220 |
Why?
|
| Health Information Exchange | 1 | 2022 | 3 | 0.210 |
Why?
|
| Middle Aged | 10 | 2020 | 8403 | 0.200 |
Why?
|
| Hemorrhage | 2 | 2020 | 75 | 0.200 |
Why?
|
| United States | 2 | 2019 | 1943 | 0.190 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2020 | 11 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2020 | 42 | 0.180 |
Why?
|
| Aged | 9 | 2019 | 8501 | 0.170 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2020 | 6 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2019 | 3220 | 0.170 |
Why?
|
| Critical Care | 2 | 2021 | 180 | 0.170 |
Why?
|
| Benchmarking | 1 | 2019 | 37 | 0.160 |
Why?
|
| Heparin | 1 | 2019 | 20 | 0.160 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 6 | 0.160 |
Why?
|
| Organ Dysfunction Scores | 1 | 2019 | 8 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2019 | 88 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 4459 | 0.150 |
Why?
|
| Glasgow Outcome Scale | 1 | 2016 | 1 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 28 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 23 | 0.130 |
Why?
|
| Cerebral Angiography | 1 | 2016 | 31 | 0.130 |
Why?
|
| Neurologic Examination | 1 | 2016 | 105 | 0.130 |
Why?
|
| Risk Factors | 2 | 2016 | 2224 | 0.120 |
Why?
|
| Patient Selection | 1 | 2016 | 170 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3231 | 0.110 |
Why?
|
| Nutritional Status | 3 | 2018 | 58 | 0.110 |
Why?
|
| Nutrition Assessment | 1 | 2013 | 45 | 0.100 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 101 | 0.100 |
Why?
|
| Malnutrition | 1 | 2013 | 22 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1336 | 0.100 |
Why?
|
| Hospital Mortality | 3 | 2019 | 131 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 195 | 0.100 |
Why?
|
| APACHE | 3 | 2019 | 26 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 1077 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 332 | 0.090 |
Why?
|
| Dietetics | 1 | 2010 | 8 | 0.090 |
Why?
|
| Norepinephrine | 1 | 2010 | 27 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2009 | 21 | 0.080 |
Why?
|
| Shock, Septic | 1 | 2010 | 57 | 0.080 |
Why?
|
| Dopamine | 1 | 2010 | 85 | 0.080 |
Why?
|
| Young Adult | 2 | 2019 | 1855 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2010 | 130 | 0.080 |
Why?
|
| Nutritional Sciences | 1 | 2008 | 4 | 0.080 |
Why?
|
| Hospitalization | 1 | 2010 | 292 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 107 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2020 | 1633 | 0.070 |
Why?
|
| Dietary Proteins | 2 | 2016 | 22 | 0.060 |
Why?
|
| Arsenicals | 1 | 2005 | 7 | 0.060 |
Why?
|
| Oxides | 1 | 2005 | 13 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 29 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 325 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 102 | 0.060 |
Why?
|
| Adolescent | 1 | 2009 | 2076 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1429 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 169 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2014 | 104 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 227 | 0.040 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2020 | 9 | 0.040 |
Why?
|
| Length of Stay | 2 | 2013 | 300 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2020 | 44 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2020 | 93 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 255 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 2020 | 81 | 0.040 |
Why?
|
| Thyroxine | 1 | 2020 | 70 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 14 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 392 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 63 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2013 | 1781 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 618 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 532 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 136 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 12 | 0.030 |
Why?
|
| Body Weight | 1 | 2014 | 137 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 31 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2013 | 24 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 190 | 0.030 |
Why?
|
| General Surgery | 1 | 2013 | 49 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 419 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 435 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 472 | 0.020 |
Why?
|
| Cost Savings | 1 | 2010 | 36 | 0.020 |
Why?
|
| Tachycardia, Sinus | 1 | 2010 | 2 | 0.020 |
Why?
|
| Vasopressins | 1 | 2010 | 8 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 124 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 28 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2010 | 62 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2008 | 16 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 126 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 256 | 0.020 |
Why?
|